Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dabrafenib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 88,541Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e
    Molecular Formula
    C24H24F3N5O5S3
    Molecular Weight
    615.7  g/mol
    InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    FDA UNII
    B6DC89I63E
    Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid
    2.1.2 InChI
    InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
    2.1.3 InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    B6DC89I63E
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1195768-06-9

    2. Dabrafenib (mesylate)

    3. Gsk 2118436b

    4. Dabrafenib Mesilate

    5. Dabrafenib Mesylate [usan]

    6. Unii-b6dc89i63e

    7. Gsk-2118436 Mesylate

    8. Gsk-2118436b

    9. Methane Sulfonate Salt

    10. Gsk2118436b

    11. Gsk2118436 Mesylate

    12. B6dc89i63e

    13. Chebi:75048

    14. Gsk-2118436b Mesylate

    15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate

    16. Gsk2118436b, Methane Sulfonate Salt

    17. Gsk-2118436 Methanesulfonate Salt

    18. Gsk-2118436b Methanesulfonate Salt

    19. Gsk2118436 Mesylate;gsk 2118436b

    20. Dabrafenib Mesilate (jan)

    21. Dabrafenib Mesylate (gsk-2118436)

    22. Dabrafenib Mesylate (usan)

    23. Dabrafenib Mesilate [jan]

    24. Taflinar

    25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid

    26. Dabrafenib Methanesulfonate

    27. Tafinlar (tn)

    28. Gsk2118436 Methane Sulfonate Salt

    29. Dabrafenib Monomesylate

    30. Gsk 2118436 Mesylate

    31. Schembl1127269

    32. Chembl2105729

    33. Dabrafenib Mesylate [mi]

    34. Dtxsid70152500

    35. Amy30045

    36. Bcp04738

    37. Ex-a1559

    38. Dabrafenib Mesilate [who-dd]

    39. Hy-14660a

    40. Mfcd20922872

    41. S5069

    42. Akos025396661

    43. Ccg-270246

    44. Cs-1641

    45. Dabrafenib Mesylate [orange Book]

    46. Ac-31302

    47. As-17010

    48. Ft-0696677

    49. D10104

    50. A903491

    51. Sr-01000941590

    52. Sr-01000941590-1

    53. Q27145089

    54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt

    55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)

    56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)

    57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate

    58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate

    59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    2.3.2 Other Synonyms

    1. 1195765-45-7

    2. Dabrafenib

    2.4 Create Date
    2009-12-22
    3 Chemical and Physical Properties
    Molecular Weight 615.7 g/mol
    Molecular Formula C24H24F3N5O5S3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count14
    Rotatable Bond Count6
    Exact Mass615.08916689 g/mol
    Monoisotopic Mass615.08916689 g/mol
    Topological Polar Surface Area210 Ų
    Heavy Atom Count40
    Formal Charge0
    Complexity910
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    * Melanoma:

    Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

    * Adjuvant treatment of melanoma:

    Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

    * Non-small cell lung cancer (NSCLC):

    Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

    Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EC02